What is Zacks Research’s Forecast for Exelixis Q1 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Exelixis in a research note issued on Monday, March 3rd. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings per share of $0.35 for the quarter, down from their previous forecast of $0.40. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q3 2025 earnings at $0.50 EPS, FY2025 earnings at $1.92 EPS, Q1 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $2.47 EPS.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

EXEL has been the topic of several other reports. BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $36.00 to $40.00 in a research note on Friday, December 20th. Stifel Nicolaus raised their price target on Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a report on Wednesday, February 12th. Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and upped their target price for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $30.00 to $40.00 in a research report on Monday, January 27th. Finally, Brookline Capital Management assumed coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.24.

Exelixis Price Performance

Exelixis stock opened at $38.65 on Thursday. The firm has a market cap of $10.82 billion, a price-to-earnings ratio of 21.84, a P/E/G ratio of 1.13 and a beta of 0.57. The firm has a fifty day moving average price of $34.81 and a two-hundred day moving average price of $31.91. Exelixis has a fifty-two week low of $20.14 and a fifty-two week high of $39.30.

Institutional Investors Weigh In On Exelixis

A number of hedge funds have recently added to or reduced their stakes in EXEL. Stephens Inc. AR bought a new stake in shares of Exelixis in the 3rd quarter valued at $251,000. Farther Finance Advisors LLC raised its stake in Exelixis by 467.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,940 shares of the biotechnology company’s stock worth $102,000 after buying an additional 3,246 shares during the period. Van ECK Associates Corp increased its stake in Exelixis by 66.2% during the 3rd quarter. Van ECK Associates Corp now owns 173,584 shares of the biotechnology company’s stock valued at $4,916,000 after purchasing an additional 69,134 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of Exelixis by 263.1% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company’s stock worth $12,536,000 after acquiring an additional 350,026 shares during the last quarter. Finally, QRG Capital Management Inc. lifted its position in Exelixis by 6.4% in the 3rd quarter. QRG Capital Management Inc. now owns 54,879 shares of the biotechnology company’s stock valued at $1,424,000 after acquiring an additional 3,321 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Christopher J. Senner sold 29,314 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares in the company, valued at $28,174,996.98. This represents a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by company insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.